DXO, short for Deschloroketamine Oxalate, is a dissociative compound within the arylcyclohexylamine class—chemically related to substances like ketamine and DCK. It acts primarily as an NMDA receptor antagonist, disrupting normal signaling in the brain and producing dissociative states. While not approved for medical use, DXO is widely explored in research and experimental psychonaut communities for its prolonged effects and clean pharmacological profile.

• NMDA receptor antagonism: DXO works by blocking NMDA (N-methyl-D-aspartate) receptors, which are involved in regulating sensory input, memory, and consciousness. This interference results in dissociation from the physical environment and altered perception of time, space, and identity.

• Structural relation to ketamine: Chemically, DXO is a derivative of ketamine with the chlorine atom removed and converted to an oxalate salt. This modification slightly alters its potency and pharmacokinetics, resulting in smoother onset and extended duration.

• Dissociative effects: At active doses, DXO induces states of detachment, dream-like introspection, ego dissolution, and altered bodily awareness—typical of NMDA antagonists. These effects are dose-dependent and can be light or profound.

• Research-only classification: DXO is not approved for therapeutic, diagnostic, or veterinary use. It is strictly sold for research purposes and should be handled with appropriate caution.

• Less anesthetic than ketamine: DXO tends to produce less physical numbness and more cognitive dissociation, making it popular for mental exploration rather than medical sedation.

• Delayed onset: Oral administration typically results in a slower onset compared to ketamine, allowing for more controlled escalation and smoother entry into the dissociative state.

The legality of DXO varies significantly across countries and even within regions. It is not scheduled under international drug control treaties, but national laws and analog acts may apply. Before ordering, it’s crucial to understand your local regulations.

• Unscheduled in most regions: DXO is not explicitly scheduled in many countries including the United States, Canada, Germany, and the UK. However, it may be considered illegal under analogue laws depending on interpretation.

• Analogue Act concerns: In countries like the U.S., DXO could potentially be classified as an analogue of ketamine, which is a controlled substance. Legal risk increases if it’s deemed intended for human consumption.

• Varying enforcement: Some customs agencies are stricter than others. Even in unscheduled jurisdictions, DXO can be seized or returned if improperly labeled or shipped.

• Psycho Plug shipping policy: We do not ship DXO to countries where it is known to be banned or where seizures are highly likely. Orders from restricted regions are blocked at checkout.

• Responsibility disclaimer: Buyers are solely responsible for understanding and complying with their country’s laws. Psycho Plug assumes no liability for legal issues after the order leaves our facility.

• Legal resources: Psychedelic law maps, discussion forums, and legal consults are useful tools for verifying status. Always use verified, updated sources for reference.

The experience of DXO is often described as deeply dissociative yet emotionally neutral, with introspective and surreal mental effects. It is less sedating than ketamine, making it appealing to those seeking extended periods of mental exploration without heavy physical incapacitation.

• Detachment from body and identity: Users frequently report a clear separation between their sense of self and physical body. This detachment can be gentle or complete, depending on dose.

• Altered perception of time and space: DXO disrupts temporal awareness, making minutes feel like hours and spatial boundaries appear fluid or nonexistent.

• Internal visualization: Many describe vivid internal imagery or dream-like sequences during the peak experience. These visuals are more abstract than psychedelic hallucinations, often resembling lucid dreams.

• Emotional neutrality: Unlike some dissociatives that evoke euphoria or catharsis, DXO tends to produce a calm, flat emotional baseline. This can reduce emotional overwhelm during deep exploration.

• Mental clarity within dissociation: Some users report that DXO allows clearer thinking during dissociation compared to PCP analogues, which are more mentally chaotic.

• Prolonged plateau phase: The duration of effects allows for sustained exploration, especially in silent or sensory-reduced environments.

• Post-trip afterglow: A sense of calm, clarity, and mental spaciousness often follows a DXO experience, lasting for several hours or even into the next day.

Proper dosing of DXO is essential to ensure accurate, safe, and reproducible research outcomes. Because it is a potent compound, precise measurement using analytical tools is mandatory. Doses should always be tailored based on the route of administration and purpose of the study.

• Light dose (5–10mg): Typically produces mild cognitive detachment, slight alteration in sensory input, and subtle time distortion. Useful for baseline observations or microdosing analysis.

• Common dose (10–25mg): Produces noticeable dissociation, disconnection from body awareness, and internal visualization. Suitable for studies exploring moderate NMDA antagonism.

• Strong dose (25–35mg or more): Leads to full dissociation, out-of-body experiences, ego loss, and significant alterations in consciousness. Should be approached with caution and monitored closely.

• Route-specific variation: Oral doses require more compound for the same effect but offer a smoother onset. Intranasal dosing requires smaller amounts but comes with a faster and sometimes more jarring experience.

• Weighing protocols: Always use a milligram-accurate digital scale (preferably 0.001g sensitivity). Eyeballing is extremely dangerous due to DXO’s potency.

• Redosing risks: Tolerance builds quickly, and redosing can lead to prolonged dissociation or unwanted side effects. Redosing should be documented carefully or avoided altogether in most research settings.

• Sitter or controlled setting: Especially for high doses, it is advisable to have a sober researcher or observer present to document responses and ensure safety.

While DXO is considered safer than many synthetic compounds when handled responsibly, it is not without risks. As a powerful NMDA antagonist, it can produce disorientation, memory disturbances, and emotional numbness—especially at high doses or with frequent use. Understanding these risks is key to responsible use and accurate research.

• Cognitive impairment: During the experience, users may lose track of time, become disoriented, or have difficulty forming coherent thoughts. This is a normal feature of dissociation but may impair data collection or self-reporting.

• Short-term memory suppression: DXO can inhibit short-term memory formation, making it difficult to recall events during the peak of its effects. This effect is dose-dependent.

• Impaired motor function: Balance, coordination, and fine motor skills are reduced, increasing the risk of falls or injury. Users should remain seated or lying down once effects begin.

• Bladder concerns with heavy use: While less studied than ketamine in this regard, chronic use of dissociatives like DXO may contribute to urinary tract or bladder issues over time.

• Potential for emotional numbing: Frequent exposure may blunt emotional responses, particularly if used as a coping mechanism. Psychological integration is important after intense experiences.

• Interaction risks: Mixing DXO with depressants (e.g., alcohol, benzodiazepines) can cause dangerous respiratory depression. It should always be used alone unless under controlled experimental conditions.

• Dependency and tolerance: While physical addiction is unlikely, psychological habituation and rapid tolerance buildup are possible. Spacing usage and setting clear intentions can reduce this risk.

The effects of DXO typically last longer than ketamine and many other dissociatives, making it a preferred option for extended exploration and study. The duration depends on the dose, route of administration, and the user’s metabolism, but most reports place the experience between 3 and 6 hours.

• Oral duration: 4–6 hours – Oral administration results in a gradual onset with a prolonged plateau phase. Effects can last up to 6 hours, with lingering after-effects for several more.

• Intranasal duration: 3–5 hours – When snorted, DXO takes effect faster and peaks sooner but may taper off slightly quicker than oral use.

• Sublingual duration: 3.5–5.5 hours – Placing the compound under the tongue may offer a middle ground between oral and nasal delivery, combining a smoother onset with moderate duration.

• Onset time: 15–30 minutes (oral), 5–15 minutes (nasal) – DXO’s onset is slower than that of ketamine, making it easier to adjust or prepare for the transition.

• Peak effects: 1–2 hours after onset – The peak is characterized by maximal dissociation, detachment, and visual distortions.

• Afterglow phase: 2–4 hours – Users commonly report an “afterglow” of mental clarity, introspection, or emotional neutrality that extends beyond the core experience.

• Longer trips with higher doses – Higher doses (25mg+) can prolong both the primary effects and the afterglow, sometimes resulting in a total arc of up to 8 hours.

DXO should be approached with caution when it comes to combining it with other substances. While some experimental combinations exist in anecdotal reports, there is limited scientific data on safety or interactions. Combining substances always increases unpredictability and potential harm.

• Avoid with depressants (alcohol, benzos) – Combining DXO with CNS depressants can dangerously amplify sedation and impair breathing. This risk is especially high at moderate to high doses.

• Stimulant combinations are risky – Pairing DXO with stimulants like amphetamines or MDMA may lead to increased confusion, anxiety, or cardiovascular strain due to conflicting neurological effects.

• Other dissociatives multiply effects – Combining DXO with ketamine, MXE, or PCP analogues significantly increases dissociative depth and unpredictability. This may result in intense ego loss or physical disconnection.

• Psychedelic combinations (e.g., LSD + DXO) – Some users experiment with combining DXO and psychedelics, reporting unusual visual and cognitive synergy. However, such combinations can be overwhelming, especially without experience or guidance.

• Serotonergic risk profile – Although DXO is not a serotonergic drug, combining it with strong serotonin agonists could increase the risk of psychological overload or serotonin-related complications.

• No clinical safety data exists – DXO has not been studied in controlled clinical settings for drug interactions. All combinations are speculative and potentially dangerous.

• Harm reduction: one substance at a time – For safe research and consistent results, it’s strongly advised to isolate variables by using DXO alone under controlled conditions.

Proper storage of DXO is critical to preserving its potency, stability, and safety over time. This is especially important for researchers or long-term users who require consistent results.

• Keep in airtight containers – Exposure to oxygen can degrade DXO over time. Use vacuum-sealed bags or tightly sealed jars to minimize air contact.

• Protect from moisture – DXO is hygroscopic and can absorb moisture from the air, leading to clumping or degradation. Silica gel packets are useful to maintain dryness.

• Store in a cool, dry environment – High temperatures accelerate chemical breakdown. A dark drawer or climate-controlled cabinet is ideal.

• Avoid exposure to light – UV and fluorescent light can alter the molecular stability of DXO. Always store it in opaque or amber containers.

• Refrigeration optional but helpful – While not required, refrigeration can extend shelf life, especially for large quantities. Ensure it is sealed to prevent condensation.

• Label with date and batch info – Keeping track of acquisition date, batch number, and purity is essential for research reproducibility and safety.

• Keep away from children and unauthorized access – DXO is not for human consumption and should be securely stored in a clearly marked, restricted location.

DXO is not considered physically addictive in the way that opioids or stimulants are, but it does carry a risk for psychological dependence, especially with frequent or escapist use. Like all dissociatives, it requires mindful use to avoid habituation.

• Low physical addiction potential – DXO does not typically produce withdrawal symptoms upon cessation. There is no evidence of physiological dependency or craving cycles.

• Psychological dependence risk – Repeated use can foster emotional detachment and avoidance behaviors, leading users to rely on the dissociative state to escape stress or trauma.

• Rapid tolerance – Tolerance builds quickly with consecutive use, often making the effects less potent even after just a few sessions. This can drive higher dosing or redosing habits.

• Dissociative habituation – Users may begin to prefer the abstracted, disconnected state of dissociation, which can interfere with emotional processing or daily responsibilities.

• No physical cravings – Unlike substances like nicotine or opioids, DXO does not create physical urges for continued use. Psychological cravings, however, can still occur.

• Spaced usage supports safety – Allowing several weeks between sessions helps maintain sensitivity and reduces risk of habitual patterns.

• Integration practices helpful – Journaling, meditation, or therapy can support healthy use and reduce the risk of falling into compulsive dissociation.

Identifying authentic DXO is essential for both safety and research integrity. Since it’s an unscheduled research chemical, there are no commercial regulations or brand standards—making source credibility and physical properties the main verification tools.

• Physical appearance – Pure DXO appears as a white or slightly off-white crystalline powder. It should be dry, uniform, and free of clumps or discoloration.

• Lack of odor – DXO should be completely odorless. Any chemical or solvent-like smell may suggest contamination or degradation.

• Certificate of Analysis (COA) – A reliable vendor like Psycho Plug provides lab verification and documentation of purity levels. This confirms chemical identity and confirms it’s free from harmful byproducts.

• Vendor transparency – Trustworthy suppliers clearly state chemical identity, class, purity, and intended use. Avoid anonymous or vague sellers.

• Uncut, unadulterated product – DXO should not be mixed with fillers, dyes, or any additives. Powder consistency and color should be uniform throughout the package.

• Verified batch details – Professional vendors mark product packaging with batch numbers and analysis dates, ensuring traceability.

• Community reputation – Check independent forums and reviews. Reputable vendors will have a track record of safety and customer satisfaction.

While DXO and ketamine are both classified as arylcyclohexylamine dissociatives, they differ in onset, intensity, medical use, and subjective effect. DXO is often seen as a more research-oriented alternative to ketamine due to its unscheduled status and longer duration, making it ideal for prolonged experimental sessions.

• Duration of effects – DXO typically lasts between 4–6 hours, significantly longer than ketamine, which averages 1–2 hours depending on dose and route. This allows for more extended observations and integration periods in research settings.

• Onset speed – Ketamine has a faster onset (especially intramuscular or intravenous), while DXO’s onset is slower and more gradual, particularly when taken orally or sublingually.

• Emotional and psychological profile – Ketamine often induces emotionally charged states, catharsis, or emotional breakthroughs. DXO is generally more emotionally neutral and introspective, making it useful for cognitive and sensory analysis.

• Physical sedation – Ketamine has stronger anesthetic properties, often causing full-body numbness and immobility. DXO is less physically sedating, with many users retaining mobility and partial coordination.

• Medical vs. research status – Ketamine is used clinically for anesthesia and treatment-resistant depression. DXO, by contrast, is a research chemical with no approved therapeutic use.

• Legal access – Ketamine is strictly controlled in most countries, requiring a prescription or license. DXO, while not approved for human use, is unscheduled in many jurisdictions and more accessible to researchers.

• Subjective clarity – DXO is often described as producing a “cleaner,” less chaotic dissociation compared to ketamine, especially at sub-anesthetic doses.

Microdosing DXO is an experimental practice in which very small, sub-threshold doses are taken to assess subtle cognitive, emotional, or functional shifts. While not clinically studied, some researchers and users explore microdosing to investigate its nootropic or introspective potential.

• Sub-perceptual dosing – Microdoses typically range from 1–3 mg, depending on the individual’s sensitivity and delivery method. These doses are below the threshold for noticeable dissociation.

• Reported benefits – Some anecdotal accounts suggest improved focus, emotional detachment from stress, and enhanced creative thinking. However, these effects are not guaranteed and vary widely.

• Lack of scientific validation – No formal research or peer-reviewed studies exist on microdosing DXO, so claims are based solely on user self-reports and community discussions.

• Tolerance development – Even at low doses, DXO can produce rapid tolerance. Microdosing daily or frequently may reduce efficacy and lead to the need for higher doses.

• Risk of accidental overdosing – The difference between a microdose and a full active dose is narrow. Without a precision scale, users may inadvertently exceed safe limits.

• Not ideal for daily use – Unlike serotonergic microdosing compounds like LSD or psilocybin, DXO’s dissociative nature may interfere with daily functioning or emotional regulation if used too frequently.

• Should be conducted under strict measurement – Anyone attempting this form of research must use an accurate milligram scale and document their observations with care.

DXO is best suited for individuals with prior experience using dissociative substances, as its extended duration, cognitive effects, and intensity may be overwhelming for newcomers. While not inherently dangerous, the depth of dissociation DXO provides can be disorienting without preparation.

• Steep learning curve – First-time users may find the detachment from body and identity difficult to navigate. The experience can be confusing without an established baseline or reference.

• Long duration may challenge comfort – DXO’s effects can last up to 6 hours, which may feel excessive or exhausting for those unaccustomed to altered states.

• Mental preparation is crucial – Unlike classic psychedelics which are often emotionally expressive, DXO induces cognitive and sensory disruption that requires a calm, curious, and flexible mindset.

• More manageable alternatives – Compounds like low-dose ketamine, or even lighter psychedelics like psilocybin, are often recommended as introductory substances before exploring DXO.

• Set and setting become critical – Beginners must take extra care to create a comfortable, distraction-free environment with minimal external stimuli.

• Sitter presence highly advised – A sober, experienced sitter can help guide first-time users, provide reassurance, and intervene if confusion or distress arises.

• Start with very low doses – If a first-time user insists on trying DXO, a dose of no more than 5mg orally is the most responsible starting point.

Yes, DXO induces tolerance similar to other dissociatives, especially when used frequently. It also demonstrates partial cross-tolerance with related NMDA antagonists, meaning that regular use may reduce sensitivity not only to DXO, but also to ketamine and PCP-like compounds.

• Rapid tolerance development – Tolerance begins building after just one or two uses, with noticeable reductions in intensity and duration by the third session if closely spaced.

• Short-term recovery window – It generally takes about 7–14 days of abstinence for baseline sensitivity to return after moderate to high doses.

• Cross-tolerance with other dissociatives – Regular use of DXO may reduce the effectiveness of ketamine, MXE, DCK, and similar compounds. The NMDA receptors involved are common targets for all of these.

• Increased dose temptation – As tolerance builds, users may increase their dosage in an attempt to “chase” previous effects, which increases the risk of overdose or unintended intensity.

• Blunted psychological effects – Emotional and cognitive responses may dull with repeated exposure, leading to a less introspective and more numbed state of dissociation.

• Recreational use accelerates tolerance – Using DXO for entertainment rather than structured research tends to result in frequent use and faster onset of tolerance.

• Harm reduction through moderation – Spacing sessions by at least two weeks, journaling experiences, and maintaining clear intentions help preserve sensitivity and reduce risk.

DXO can be administered through multiple routes, with oral and intranasal being the most common. Each method produces distinct onset times, peak intensities, and durations, which researchers should consider when designing studies or personal protocols.

• Oral ingestion (swallowed) – Offers the smoothest and longest-lasting experience. Onset begins at 15–30 minutes, with effects lasting up to 6 hours. This route is ideal for controlled, gradual studies.

• Intranasal (snorted) – Absorbed more rapidly through the nasal mucosa, with onset in 5–15 minutes. Peak intensity is faster and sometimes sharper, but duration is slightly shorter than oral.

• Sublingual (under the tongue) – Allows for partial mucosal absorption and avoids first-pass metabolism. Onset is between oral and intranasal, with a smoother initial build-up.

• Rectal administration (suppository or liquid) – Anecdotal reports suggest efficient absorption and moderate potency, but this route is less common and under-researched.

• No injection routes – DXO is not designed for intravenous or intramuscular use. Such methods are strongly discouraged due to unknown pharmacokinetics and safety concerns.

• Accurate measurement required for all routes – Milligram-scale accuracy is critical to avoid accidental overdosing, especially when using concentrated forms.

• Route affects set and setting – Intranasal use may require a more immediate safe space due to faster onset, while oral use allows more preparation time.